

## **Radiopharm Theranostics to host Pivalate educational webinar**

Sydney, Australia – 13 June 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it will host an educational webinar on its Pivalate platform technology for shareholders and interested parties.

Radiopharm CEO and Managing Director Riccardo Canevari will provide an overview on the encouraging pre-IND meeting with FDA, Pivalate late-stage development plan and market opportunity. An opportunity to ask questions will also be provided.

**When: 11am AEST, Wednesday 14 June 2023**

**Register at: [https://us02web.zoom.us/webinar/register/WN\\_Sf5aGJdJRLCYVxxcbWAEAA](https://us02web.zoom.us/webinar/register/WN_Sf5aGJdJRLCYVxxcbWAEAA)**

Upon registering attendees will receive an email containing information about joining the webinar. A recording will be available at the above link soon after the conclusion of the live session, with the replay to also be made available via Radiopharm’s website and social media channels.

Questions can be sent in advance of the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### **About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first to market or best in class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, lung and brain. Learn more at [RadiopharmTheranostics.com](http://RadiopharmTheranostics.com).

**Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.**

### **For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Paul Hopper  
Executive Chairman  
P: +61 406 671 515  
E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

**ASX ANNOUNCEMENT  
13 JUNE 2023**



Timothy McCarthy  
Investor Relations  
LifeSci Advisors, LLC  
P: +1 917 679 9282  
E: [tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>